Sacavce

Human Centriole and Centrosome Antibody IgG ELISA Kit
MBS039049-10x96StripWells 10x96-Strip-Wells
EUR 6725

Human IgG antibody Laboratories manufactures the sacavce reagents distributed by Genprice. The Sacavce reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Sacace Srl.. Other Sacavce products are available in stock. Specificity: Sacavce Category:

Human True insulin ELISA kit
1 plate of 96 wells
EUR 822
Description: A competitive ELISA for quantitative measurement of Human True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Human True insulin ELISA kit
96T
EUR 700
Description: ELISA

Human True Insulin ELISA Kit
10x96-Strip-Wells
EUR 6725

Human True Insulin ELISA Kit
48-Strip-Wells
EUR 550

Human True Insulin ELISA Kit
5x96-Strip-Wells
EUR 3420

Human True Insulin ELISA Kit
96-Strip-Wells
EUR 765

Human True Insulin GENLISA ELISA
1 x 96 wells
EUR 286

Chemicals information

SaCas9 mAb (Clone 11E7), sample
MBS389045-5x01mg 5x0.1mg
EUR 2755

saCas9 Nuclease Protein
K044 6.5 µg (50pmol) Volume: 50µL
EUR 55
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT).

saCas9 Null Mutant Protein
K046 6.5 µg (50pmol) Volume: 50µL
EUR 55
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The saCas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type saCas9. Such a saCas9 protein retains its ability to bind to genomic DNA through sgRNA:genomic DNA base pairing, however, the saCas9 Null Mutant does not induce cleavage. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT).

saCas9 Nuclease Protein
MBS4156505-00065mg 0.0065mg
EUR 210

saCas9 Nuclease Protein
MBS4156505-5x00065mg 5x0.0065mg
EUR 630

saCas9 Null Mutant Protein
MBS4156507-00065mg 0.0065mg
EUR 210

saCas9 Null Mutant Protein
MBS4156507-5x00065mg 5x0.0065mg
EUR 630

saCas9 Nuclease Protein
MBS4156520-003mg 0.03mg
EUR 275

saCas9 Nuclease Protein
MBS4156520-5x003mg 5x0.03mg
EUR 915

saCas9 Null Mutant Protein
MBS4156522-003mg 0.03mg
EUR 275

saCas9 Null Mutant Protein
MBS4156522-5x003mg 5x0.03mg
EUR 915

AbFlex SaCas9 antibody (rAb)
MBS389497-001mg 0.01mg
EUR 165

AbFlex SaCas9 antibody (rAb)
MBS389497-01mg 0.1mg
EUR 465

AbFlex SaCas9 antibody (rAb)
MBS389497-5x01mg 5x0.1mg
EUR 2025

saCas9 Null Mutant NLS Protein
K047 6.5 µg (50pmol) Volume: 50µL
EUR 55
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The saCas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type saCas9. Such a saCas9 protein retains its ability to bind to genomic DNA through gRNA:genomic DNA base pairing, however, the saCas9 Null Mutant does not introduce any genome modifications. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). saCas9 NLS Null Mutant contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein.

saCas9 Nuclease AAV Virus (AAV4)
K211 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml
EUR 375
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing.

saCas9 Nuclease AAV Virus (AAV5)
K212 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml
EUR 375
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing.